within Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX05_Lutetium177luVipivotideTetraxetan;

model Lutetium177luVipivotideTetraxetan
  extends Pharmacolibrary.Drugs.ATC.V.V10XX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V10XX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lutetium (177Lu) vipivotide tetraxetan (INN; formerly known as lutetium-177 PSMA-617, trade name Pluvicto) is a radioligand therapeutic used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Administered intravenously, it delivers targeted radiation to PSMA-expressing cancer cells. It is approved for clinical use in certain advanced prostate cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult male patients with PSMA-positive metastatic castration-resistant prostate cancer following intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lutetium177luVipivotideTetraxetan;
